Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting

被引：1
|
作者：
Moshel, Shai
Vexberg, Michal Hirsch
Shavit, Oren
Toledano, Yoel
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1297-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING
    Moshel, S.
    Vexberg, Hirsch M.
    Shavit, O.
    Toledano, Y.
    VALUE IN HEALTH, 2018, 21 : S131 - S131
  • [2] Economic evaluation of dapagliflozin as add-on to metformin in type 2 diabetes in the Israeli healthcare setting
    Moshel, S.
    Vexberg, M. Hirsch
    Shavit, O.
    Toledano, Y.
    DIABETOLOGIA, 2018, 61 : S311 - S311
  • [3] Add-on to metformin in T2DM—linagliptin or glimepiride?
    Mikkel Christensen
    Filip K. Knop
    Nature Reviews Endocrinology, 2012, 8 : 576 - 578
  • [4] Long-Term Efficacy of Dapagliflozin as Add-On to Metformin (MET) in T2DM Inadequately Controlled with MET Alone
    Bailey, Clifford J.
    Gross, Jorge L.
    Yadav, Manoj
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    DIABETES, 2011, 60 : A271 - A271
  • [5] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [6] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
    Toplak, H
    Vercruysse, F
    Sun, X
    Fitchet, M
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
  • [7] Efficacy and Safety of Saxagliptin Add-on to Metformin Compared with Acarbose Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy
    Du, Jin
    Liang, Li
    Fang, Hui
    Xu, Fengmei
    Li, Wei
    Shen, Liya
    Mu, Yiming
    DIABETES, 2016, 65 : A293 - A293
  • [8] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [9] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?
    Christensen, Mikkel
    Knop, Filip K.
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (10) : 576 - 578
12345